Back to discover
Disease

Hypopituitarism

Late-stage therapeutic developmentEmerging research
MeSHHypopituitarism
2
Publications
9
Clinical trials
2023
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

Executive briefingUpdating summary…Momentum: Low
Key developments
  • 1 clinical trial expected to report results, the earliest in Q2 2027.
Upcoming Milestones
Major developments
Upcoming trial readoutImportant
Identifying a Provocation Test for Diagnosis of Oxytocin Deficiency in Youth With Hypopituitarism
Results expected Q2 20272026-05-15
Clinical Milestones1View
Results expected 1
Activity timeline1

Clinical trials

7 sponsors · 1 new · 0 completed in the last 12 months (net +1)

The current development programme across all trial phases.

Clinical programme
9
All trials
2
Active
6
Late-stage
6
Completed
Late-stage studies

Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)

Phase 4 · Completed · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept Physiopathological Study (CRH Study)

Phase 4 · Completed · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Physiologic Testosterone Replacement in Women With Hypopituitarism

Phase 4 · Completed · Charles Drew University of Medicine and Science

Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium

Phase 4 · Completed · A.O.U. Città della Salute e della Scienza

Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes

Phase 4 · Completed · A.O.U. Città della Salute e della Scienza

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults

Phase 3 · Completed · Stanford University
Recently completed

Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept, Physiopathological Study (GLP1 Study)

Phase 4 · Completed · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Identification and Clinical Relevance of an Oxytocin Deficient State: a Randomized, Crossover, Placebo-controlled, Proof-of-concept Physiopathological Study (CRH Study)

Phase 4 · Completed · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau

Acute Neuroendocrine Response to Intravenous Infusion of Diclofenac Sodium

Phase 4 · Completed · A.O.U. Città della Salute e della Scienza

Stimulation Test With Intranasal Glucagon for Corticotroph, Somatotroph and Antidiuretic Axes

Phase 4 · Completed · A.O.U. Città della Salute e della Scienza

Effects of Growth Hormone on Cognition and Cerebral Metabolism in Adults

Phase 3 · Completed · Stanford University

Physiologic Testosterone Replacement in Women With Hypopituitarism

Phase 4 · Completed · Charles Drew University of Medicine and Science

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Publications over time
20142023
Major themes3
  • Dwarfism, Pituitary1
  • Human Growth Hormone1
  • Hypopituitarism1
Leading journals2
  • Frontiers in endocrinology1
  • The Journal of clinical endocrinology and metabolism1
Leading researchers8
  • Antoniazzi F1
  • Cavarzere P1
  • Fadden R1
  • Faje AT1
  • Guzzo A1
  • Klibanski A1
  • Lawrence D1
  • Nachtigall L1
Affiliations (unnormalised)3
  • Massachusetts General Hospital and Harvard Medical School1
  • School of Medicine1
  • University of Verona1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Diminution or cessation of secretion of one or more hormones from the anterior pituitary gland (including LH; FOLLICLE STIMULATING HORMONE; SOMATOTROPIN; and CORTICOTROPIN). This may result from surgical or radiation ablation, non-secretory PITUITARY NEOPLASMS, metastatic tumors, infarction, PITUITARY APOPLEXY, infiltrative or granulomatous processes, and other conditions.

Identifiers
MeSHHypopituitarism
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.